Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

2.

A Targeted Mass Spectrometry Assay for Detection of HIV Gag Protein Following Induction of Latent Viral Reservoirs.

Schlatzer D, Haqqani AA, Li X, Dobrowolski C, Chance MR, Tilton JC.

Anal Chem. 2017 May 16;89(10):5325-5332. doi: 10.1021/acs.analchem.6b05070. Epub 2017 May 3.

PMID:
28467046
3.

High sensitivity detection and sorting of infectious human immunodeficiency virus (HIV-1) particles by flow virometry.

Bonar MM, Tilton JC.

Virology. 2017 May;505:80-90. doi: 10.1016/j.virol.2017.02.016. Epub 2017 Feb 21.

4.

HIV signaling through CD4 and CCR5 activates Rho family GTPases that are required for optimal infection of primary CD4+ T cells.

Lucera MB, Fleissner Z, Tabler CO, Schlatzer DM, Troyer Z, Tilton JC.

Retrovirology. 2017 Jan 24;14(1):4. doi: 10.1186/s12977-017-0328-7.

5.

Central memory CD4+ T cells are preferential targets of double infection by HIV-1.

Haqqani AA, Marek SL, Kumar J, Davenport M, Wang H, Tilton JC.

Virol J. 2015 Nov 11;12:184. doi: 10.1186/s12985-015-0415-0.

6.

The histone deacetylase inhibitor vorinostat (SAHA) increases the susceptibility of uninfected CD4+ T cells to HIV by increasing the kinetics and efficiency of postentry viral events.

Lucera MB, Tilton CA, Mao H, Dobrowolski C, Tabler CO, Haqqani AA, Karn J, Tilton JC.

J Virol. 2014 Sep;88(18):10803-12. doi: 10.1128/JVI.00320-14. Epub 2014 Jul 9.

7.

Copper limits: opportunity costs.

Tilton JE.

Science. 2014 May 9;344(6184):577-8. doi: 10.1126/science.344.6184.577-b. No abstract available.

PMID:
24812380
8.

CD4+ memory stem cells are infected by HIV-1 in a manner regulated in part by SAMHD1 expression.

Tabler CO, Lucera MB, Haqqani AA, McDonald DJ, Migueles SA, Connors M, Tilton JC.

J Virol. 2014 May;88(9):4976-86. doi: 10.1128/JVI.00324-14. Epub 2014 Feb 19.

9.

A combination HIV reporter virus system for measuring post-entry event efficiency and viral outcome in primary CD4+ T cell subsets.

Tilton CA, Tabler CO, Lucera MB, Marek SL, Haqqani AA, Tilton JC.

J Virol Methods. 2014 Jan;195:164-9. doi: 10.1016/j.jviromet.2013.08.029. Epub 2013 Sep 8.

10.

Entry inhibitors and their use in the treatment of HIV-1 infection.

Haqqani AA, Tilton JC.

Antiviral Res. 2013 May;98(2):158-70. doi: 10.1016/j.antiviral.2013.03.017. Epub 2013 Mar 28. Review.

PMID:
23541872
11.

Multifaceted mechanisms of HIV inhibition and resistance to CCR5 inhibitors PSC-RANTES and Maraviroc.

Lobritz MA, Ratcliff AN, Marozsan AJ, Dudley DM, Tilton JC, Arts EJ.

Antimicrob Agents Chemother. 2013 Jun;57(6):2640-50. doi: 10.1128/AAC.02511-12. Epub 2013 Mar 25.

12.

HIV: cell binding and entry.

Wilen CB, Tilton JC, Doms RW.

Cold Spring Harb Perspect Med. 2012 Aug 1;2(8). pii: a006866. doi: 10.1101/cshperspect.a006866. Review.

13.

Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin α4β7.

Parrish NF, Wilen CB, Banks LB, Iyer SS, Pfaff JM, Salazar-Gonzalez JF, Salazar MG, Decker JM, Parrish EH, Berg A, Hopper J, Hora B, Kumar A, Mahlokozera T, Yuan S, Coleman C, Vermeulen M, Ding H, Ochsenbauer C, Tilton JC, Permar SR, Kappes JC, Betts MR, Busch MP, Gao F, Montefiori D, Haynes BF, Shaw GM, Hahn BH, Doms RW.

PLoS Pathog. 2012;8(5):e1002686. doi: 10.1371/journal.ppat.1002686. Epub 2012 May 31.

14.

Molecular mechanisms of HIV entry.

Wilen CB, Tilton JC, Doms RW.

Adv Exp Med Biol. 2012;726:223-42. doi: 10.1007/978-1-4614-0980-9_10. Review.

PMID:
22297516
15.

Primary infection by a human immunodeficiency virus with atypical coreceptor tropism.

Jiang C, Parrish NF, Wilen CB, Li H, Chen Y, Pavlicek JW, Berg A, Lu X, Song H, Tilton JC, Pfaff JM, Henning EA, Decker JM, Moody MA, Drinker MS, Schutte R, Freel S, Tomaras GD, Nedellec R, Mosier DE, Haynes BF, Shaw GM, Hahn BH, Doms RW, Gao F.

J Virol. 2011 Oct;85(20):10669-81. doi: 10.1128/JVI.05249-11. Epub 2011 Aug 10.

16.

Phenotypic and immunologic comparison of clade B transmitted/founder and chronic HIV-1 envelope glycoproteins.

Wilen CB, Parrish NF, Pfaff JM, Decker JM, Henning EA, Haim H, Petersen JE, Wojcechowskyj JA, Sodroski J, Haynes BF, Montefiori DC, Tilton JC, Shaw GM, Hahn BH, Doms RW.

J Virol. 2011 Sep;85(17):8514-27. doi: 10.1128/JVI.00736-11. Epub 2011 Jun 29.

17.

Engineering HIV-resistant human CD4+ T cells with CXCR4-specific zinc-finger nucleases.

Wilen CB, Wang J, Tilton JC, Miller JC, Kim KA, Rebar EJ, Sherrill-Mix SA, Patro SC, Secreto AJ, Jordan AP, Lee G, Kahn J, Aye PP, Bunnell BA, Lackner AA, Hoxie JA, Danet-Desnoyers GA, Bushman FD, Riley JL, Gregory PD, June CH, Holmes MC, Doms RW.

PLoS Pathog. 2011 Apr;7(4):e1002020. doi: 10.1371/journal.ppat.1002020. Epub 2011 Apr 14.

18.

A maraviroc-resistant HIV-1 with narrow cross-resistance to other CCR5 antagonists depends on both N-terminal and extracellular loop domains of drug-bound CCR5.

Tilton JC, Wilen CB, Didigu CA, Sinha R, Harrison JE, Agrawal-Gamse C, Henning EA, Bushman FD, Martin JN, Deeks SG, Doms RW.

J Virol. 2010 Oct;84(20):10863-76. doi: 10.1128/JVI.01109-10. Epub 2010 Aug 11.

19.

HIV-1 resistance to CCR5 antagonists associated with highly efficient use of CCR5 and altered tropism on primary CD4+ T cells.

Pfaff JM, Wilen CB, Harrison JE, Demarest JF, Lee B, Doms RW, Tilton JC.

J Virol. 2010 Jul;84(13):6505-14. doi: 10.1128/JVI.00374-10. Epub 2010 Apr 21.

20.

HIV type 1 from a patient with baseline resistance to CCR5 antagonists uses drug-bound receptor for entry.

Tilton JC, Amrine-Madsen H, Miamidian JL, Kitrinos KM, Pfaff J, Demarest JF, Ray N, Jeffrey JL, Labranche CC, Doms RW.

AIDS Res Hum Retroviruses. 2010 Jan;26(1):13-24. doi: 10.1089/aid.2009.0132.

21.

Entry inhibitors in the treatment of HIV-1 infection.

Tilton JC, Doms RW.

Antiviral Res. 2010 Jan;85(1):91-100. doi: 10.1016/j.antiviral.2009.07.022. Epub 2009 Aug 14. Review.

PMID:
19683546
22.

Comparisons of CD8+ T cells specific for human immunodeficiency virus, hepatitis C virus, and cytomegalovirus reveal differences in frequency, immunodominance, phenotype, and interleukin-2 responsiveness.

Jagannathan P, Osborne CM, Royce C, Manion MM, Tilton JC, Li L, Fischer S, Hallahan CW, Metcalf JA, McLaughlin M, Pipeling M, McDyer JF, Manley TJ, Meier JL, Altman JD, Hertel L, Davey RT Jr, Connors M, Migueles SA.

J Virol. 2009 Mar;83(6):2728-42. doi: 10.1128/JVI.02128-08. Epub 2009 Jan 7.

23.

Human immunodeficiency virus viremia induces plasmacytoid dendritic cell activation in vivo and diminished alpha interferon production in vitro.

Tilton JC, Manion MM, Luskin MR, Johnson AJ, Patamawenu AA, Hallahan CW, Cogliano-Shutta NA, Mican JM, Davey RT Jr, Kottilil S, Lifson JD, Metcalf JA, Lempicki RA, Connors M.

J Virol. 2008 Apr;82(8):3997-4006. doi: 10.1128/JVI.01545-07. Epub 2008 Feb 6.

24.

Changes in paracrine interleukin-2 requirement, CCR7 expression, frequency, and cytokine secretion of human immunodeficiency virus-specific CD4+ T cells are a consequence of antigen load.

Tilton JC, Luskin MR, Johnson AJ, Manion M, Hallahan CW, Metcalf JA, McLaughlin M, Davey RT Jr, Connors M.

J Virol. 2007 Mar;81(6):2713-25. Epub 2006 Dec 20.

25.

Diminished production of monocyte proinflammatory cytokines during human immunodeficiency virus viremia is mediated by type I interferons.

Tilton JC, Johnson AJ, Luskin MR, Manion MM, Yang J, Adelsberger JW, Lempicki RA, Hallahan CW, McLaughlin M, Mican JM, Metcalf JA, Iyasere C, Connors M.

J Virol. 2006 Dec;80(23):11486-97. Epub 2006 Sep 27.

26.

CD4+ immune escape and subsequent T-cell failure following chimpanzee immunization against hepatitis C virus.

Puig M, Mihalik K, Tilton JC, Williams O, Merchlinsky M, Connors M, Feinstone SM, Major ME.

Hepatology. 2006 Sep;44(3):736-45.

PMID:
16941702
27.

Qualitative host factors associated with immunological control of HIV infection by CD8 T cells.

Migueles SA, Tilton JC, Connors M.

Curr Opin HIV AIDS. 2006 Jan;1(1):28-33. doi: 10.1097/01.COH.0000194108.14601.69.

PMID:
19372780
28.

Advances in understanding immunologic control of HIV infection.

Migueles SA, Tilton JC, Connors M.

Curr HIV/AIDS Rep. 2004 Apr;1(1):12-7. Review.

PMID:
16091218
29.

Molecular basis for positive and negative signaling by the natural killer cell receptor 2B4 (CD244).

Eissmann P, Beauchamp L, Wooters J, Tilton JC, Long EO, Watzl C.

Blood. 2005 Jun 15;105(12):4722-9. Epub 2005 Feb 15.

30.

Diminished proliferation of human immunodeficiency virus-specific CD4+ T cells is associated with diminished interleukin-2 (IL-2) production and is recovered by exogenous IL-2.

Iyasere C, Tilton JC, Johnson AJ, Younes S, Yassine-Diab B, Sekaly RP, Kwok WW, Migueles SA, Laborico AC, Shupert WL, Hallahan CW, Davey RT Jr, Dybul M, Vogel S, Metcalf J, Connors M.

J Virol. 2003 Oct;77(20):10900-9.

Supplemental Content

Loading ...
Support Center